Symposia: Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Sickle Cell Disease, Combination therapy, Research, Clinical trials, Drug development, Clinical Research, Hemoglobinopathies, Diseases, Treatment Considerations
Type: Oral
Hematology Disease Topics & Pathways:
Sickle Cell Disease, Combination therapy, Research, Clinical trials, Drug development, Clinical Research, Hemoglobinopathies, Diseases, Treatment Considerations
Sunday, December 8, 2024: 12:00 PM-1:30 PM
Room 28 A-D
(San Diego Convention Center)
Moderators:
Parul Rai, MD, MBBS, St. Jude Children’s Research Hospital
and
Valentine Brousse, MD, PhD, ARRAY(0xfda5658)
Disclosures:
Brousse: Novartis: Other: adjudication comitee; Pfizer: Membership on an entity's Board of Directors or advisory committees; Vertex: Consultancy; NovoNordisk: Consultancy; Nuvamid: Consultancy.
Although hydroxyurea has been around for some time, its full benefits are being realized not just in the US and Europe, but in Africa. This session will update some of the known and previously under-explored benefits of hydroxyurea. Newer medications are also being discussed.
12:00 PM
12:15 PM
12:30 PM
12:45 PM
1:00 PM
1:15 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH